Clinical trials
Every registered trial of Dulaglutide
127 studies, 13 still enrolling.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Dulaglutide has a real but limited body of human research.
- 127 registered studies in total.
- 13 are still enrolling people, so this is active research, not just history.
What kind of research
- 114 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 58,872 people took part in those.
- A further 13 studies only looked at records of people already taking it. These are counted separately because nobody was given the peptide for the study, so they cannot prove cause and effect.
How far along it is
- 57 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 54 have published results in the medical literature that anyone can read.
- The research spans 51 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 127 of 127 trials for Dulaglutide.
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus
ProGen. Co., Ltd.
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company
Diabetes Mellitus, Type 2
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
First Affiliated Hospital of Wannan Medical College
T2DM (Type 2 Diabetes Mellitus) · CKD - Chronic Kidney Disease
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.
Brigham and Women's Hospital
Type 2 Diabetes
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Brigham and Women's Hospital
Type 2 Diabetes · Overweight · ASCVD
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
Brigham and Women's Hospital
Type 2 Diabetes Mellitus · Obesity · Overweight
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
Type 2 Diabetes Mellitus (T2DM)
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
National University of Singapore
Intracranial Atherosclerosis · Stroke, Ischemic
A Phase 3 Study of HS-20094 in Patients With T2DM
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type 2 Diabetes
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus
Ain Shams University
Menstrual Irregularities · Type1 Diabetes Mellitus · Glucagon-Like Peptide-1 Receptor Agonists · Female Reproductive Health
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Fundación para la Investigación del Hospital Clínico de Valencia
Diabetes Mellitus Type 2
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company
Type 2 Diabetes
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
MaryAnn Banerji
Type 2 Diabetes (T2DM)
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia
Ain Shams University
Transfusion Dependent Beta Thalassemia
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Brigham and Women's Hospital
Type 2 Diabetes
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data
Brigham and Women's Hospital
Type 2 Diabetes · Major Adverse Cardiac Events · Cardiovascular (CV) Risk
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Brigham and Women's Hospital
Type 2 Diabetes · Overweight · Cardiovascular (CV) Risk
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
The Cleveland Clinic
Diabetes Mellitus, Type 2 · Obesity · Gastroparesis
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
Beijing Dongfang Biotech Co., Ltd.
Type2 Diabetes Mellitus
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: a single-arm interventional clinical trial. Study 2: Patients on the waiting list for kidney transplantation.
Bellvitge University Hospital, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
Metabolic syndrome in patients on the waiting list for kidney transplantation, Metabolic syndrome in patients on the waiting list for kidney transplantation
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
The University of Hong Kong
Myocardial Injury
A Study of HS-20094 in Patients With T2DM
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type 2 Diabetes
GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: randomized clinical trial. Study 1: Immediate Kidney Transplant Recipients
Bellvitge University Hospital, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
Preventive treatment of post-kidney transplant diabetes
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus
Dongguan HEC Biopharmaceutical R&D Co., Ltd.
Type 2 Diabetes
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
Seoul National University Bundang Hospital
Metabolic-associated Fatty Liver Disease · Type 2 Diabetes
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
AdventHealth Translational Research Institute
Diabetes Mellitus, Type 1 · Endothelial Dysfunction
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Cardenal Herrera University
Chronic Kidney Disease stage3 · Chronic Kidney Disease stage4 · Chronic Kidney Disease Stage 1 · Chronic Kidney Disease Stage 2
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity
First Affiliated Hospital of Zhejiang University
Bipolar Disorder · Obesity · Cognition
I8F-MC-GPIH
Eli Lilly Cork Limited
Type 2 Diabetes
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Hangzhou Sciwind Biosciences Co., Ltd.
T2DM · Type 2 Diabetes Mellitus
A Study of IBI362 in Participants With Type 2 Diabetes
Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
Eli Lilly and Company
Type 2 Diabetes
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus
Fujian Shengdi Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Brigham and Women's Hospital
Type2Diabetes · ASCVD
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
A Study of TG103 Injection in Type 2 Diabetes Subjects
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects
Sunshine Lake Pharma Co., Ltd.
Type 2 Diabetes
Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease
Vanderbilt University Medical Center
Chronic Kidney Diseases
Basal Plus GLP1-ra on Glycemic Variability in CKD
Elaine Chow
Diabetes Mellitus · Diabetic Kidney Disease
Dulaglutide for peritoneal dialysis in diabetic kidney disease
Chang Gung Memorial Hospital
Diabetes and peritoneal dialysis
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy
The Affiliated Hospital of Xuzhou Medical University
Type 2 Diabetic Nephropathy
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
Type 2 Diabetes
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes
Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients
Emory University
Hyperglycemia Stress
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital
Cardiovascular Events · Type2 Diabetes · Renal Disease
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
University of Pennsylvania
Cystic Fibrosis · Pancreatic Insufficiency · Abnormal Glucose Tolerance · Diabetes
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
Brigham and Women's Hospital
Diabetes Mellitus, Type 2
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)
Shanghai 10th People's Hospital
Polycystic Ovary Syndrome
A Study of LY3437943 in Participants With Type 2 Diabetes
Eli Lilly and Company
Type 2 Diabetes
Effects of Glucagon-Like Peptide-1 Analogs on Sexuality
University Hospital, Basel, Switzerland
Sexual Functioning
The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.
Second Xiangya Hospital of Central South University
Diabetes Mellitus, Type 2 · Overweight or Obesity
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
Eli Lilly and Company
Diabetes Mellitus · Diabetes Mellitus, Type 2 · Glucose Metabolism Disorders · Metabolic Disease
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes
Eli Lilly and Company
Healthy · Type 2 Diabetes
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes
A Study of LY3493269 in Participants With Type 2 Diabetes
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company
Type 2 Diabetes Mellitus
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
Chungbuk National University Hospital
Type 2 Diabetes Mellitus · Glucose, High Blood
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
The University of Texas Health Science Center, Houston
Glucose Intolerance · Overweight and Obesity · Drug Effect · Adiposity
Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes
Shanghai Zhongshan Hospital
Type 2 Diabetes
Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin
Corporacion Parc Tauli
Type 2 Diabetes Treated With Insulin · Obesity · Adolescent Obesity
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
Eli Lilly and Company
Diabetes Mellitus, Type 2
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
Novo Nordisk A/S
Healthy Volunteers · Diabetes Mellitus, Type 2 · Overweight · Obesity
Semaglutide vs Dulaglutide on Epicardial Adipose Tissue
University of Miami
Epicardial Fat
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)
Central Hospital, Nancy, France
Diabetes Mellitus, Type 2 · NASH - Nonalcoholic Steatohepatitis
A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
Eli Lilly and Company
Type 2 Diabetes
Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients
Emory University
Stress Hyperglycemia
Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes
Hospices Civils de Lyon
Adult Subjects With Type1Diabetes and Insulin Microsecretion
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Medanta, The Medicity, India
Non Alcoholic Fatty Liver Disease · Type2 Diabetes Mellitus
GLP-1 REceptor Agonists and Real World EvIdeNce
University of Padova
Type 2 Diabetes
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
Eli Lilly and Company
Diabetes Mellitus, Type 2
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Sanofi
Type 2 Diabetes Mellitus
Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)
National and Kapodistrian University of Athens
Non-Alcoholic Fatty Liver Disease · Liver Steatosis
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
Eli Lilly and Company
Diabetes Mellitus, Type 2
The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria
Attikon Hospital
Urine Albumin (UAlb) · Glycocalyx · Arterial Stiffness
A Study of Dulaglutide in Healthy Participants
Eli Lilly and Company
Healthy
Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes
University of Guadalajara
Diabetes Mellitus, Type 2
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
Eli Lilly and Company
Type 2 Diabetes
Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues
University Hospital, Basel, Switzerland
Glucagon-like Peptide-1 · Smoking Cessation · Weight Change, Body · Craving
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
Type 2 Diabetes Mellitus
Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
University of Palermo
Diabetes Mellitus
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/S
Diabetes · Diabetes Mellitus, Type 2
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
Eli Lilly and Company
Type 2 Diabetes
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy
Eli Lilly and Company
Type 2 Diabetes
Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake
University Hospital, Basel, Switzerland
Thirst · Water-Electrolyte Imbalance
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
Eli Lilly and Company
Type 2 Diabetes
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
University of California, San Francisco
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Sanofi
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
Eli Lilly and Company
Healthy · Type 2 Diabetes Mellitus (T2DM)
Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)
University Hospital, Basel, Switzerland
Primary Polydipsia
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
Novo Nordisk A/S
Diabetes · Diabetes Mellitus, Type 2
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
Eli Lilly and Company
Diabetes Mellitus, Type 2
Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Dulaglutide in Chinese Participants
Eli Lilly and Company
Diabetes Mellitus, Type 2 · Healthy Volunteers
A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus
Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
Eli Lilly and Company
Type 2 Diabetes · Chronic Kidney Disease
A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
Eli Lilly and Company
Type 2 Diabetes
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
Eli Lilly and Company
Diabetes Mellitus, Type 2
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Eli Lilly and Company
Cardiovascular Disease · Diabetes Mellitus, Type 2
A Study of the Effect of LY2189265 on Two Blood Pressure Drugs
Eli Lilly and Company
Diabetes Mellitus, Type 2
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.
Eli Lilly and Company
Diabetes Mellitus, Type II
LY2189265 and Atorvastatin Interaction Study
Eli Lilly and Company
Healthy Volunteers
A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY2189265 in Japanese Patients With Type 2 Diabetes
Eli Lilly and Company
Diabetes Mellitus, Type 2
Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
Diabetes Mellitus Type 2
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Dulaglutide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.